Increasing Incidence and Prevalence of Acquired Hemolytic Anemias in Denmark, 1980-2016

Overview

Journal Clin Epidemiol

Publisher Dove Medical Press

Specialty Public Health

Date 2020 Jun 18

PMID 32547241

Citations 22

Authors

Dennis Lund Hansen

Soren Moller

Kjeld Andersen

David Gaist

Henrik Frederiksen

Affiliations

Soon will be listed here.

Abstract

Background: Acquired hemolytic disorders-autoimmune hemolytic anemia (AIHA), cold agglutinin disease (CAD), paroxysmal nocturnal hemoglobinuria (PNH), drug-induced hemolysis (DIHA), and acquired hemolysis not otherwise specified (AHNOS)-are considered rare. Despite their potentially major health implications, data regarding their incidence and prevalence are scarce.

Methods: To fill this gap we collected data regarding all patients with acquired hemolytic disorder diagnoses in 1977-2016 from the Danish National Patient Register. These data were linked with vital and migration status information from the Danish Civil Registration System. From these data combined with annual demographic data for the background population, we calculated age- and sex-specific incidence rates and prevalence proportions of acquired hemolytic disorders for specified time periods.

Results: Our analysis included 5868 patients with acquired hemolytic disorders (2715 with AIHA, 112 CAD, 397 DIHA, 116 PNH, and 2154 AHNOS). The incidence rates per 100 000 person-years in 1980-1993 and 2008-2016 were 0.81 and 1.77 for AIHA, 0.31 and 0.12 for DIHA, and 0.04 and 0.08 for PNH, respectively. The 2008-2016 CAD incidence rate was 0.18/100 000 person-years, CAD diagnosis code was not defined before 1994. All incidence rates increased with age. The prevalence proportion per 100 000 persons in 1980 and 2015 was 2.52 and 17.01 for AIHA, 0.80 and 1.50 for DIHA, and 0.18 and 1.04 for PNH. CAD prevalence in 2015 was 1.04/100 000 persons.

Conclusion: Acquired hemolytic anemia incidence rates and prevalence proportions with the exception of DIHA are markedly increasing.

Citing Articles

Insight Into Aetiology and Severity of Hemolysis Associated with Immunoproteins on Red Cell Surface in Direct Antiglobulin Test Positive Auto-immune Hemolytic Anemia.

Sil S, Kaur D, Negi G, Jain A, Nath U Indian J Hematol Blood Transfus. 2025; 41(1):127-136.

PMID: 39917501 PMC: 11794771. DOI: 10.1007/s12288-024-01805-y.

Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

Sampei Z, Haraya K, Gan S, Muraoka M, Hayasaka A, Fukuzawa T Int J Mol Sci. 2024; 25(21).

PMID: 39519232 PMC: 11546984. DOI: 10.3390/ijms252111679.

Autoimmune haemolytic anaemias.

Michel M, Crickx E, Fattizzo B, Barcellini W Nat Rev Dis Primers. 2024; 10(1):82.

PMID: 39487134 DOI: 10.1038/s41572-024-00566-2.

Overall Survival and Treatment Patterns Among Patients With Warm Autoimmune Hemolytic Anemia in Sweden: A Nationwide Population-based Study.

Cherif H, Cai Q, Crivera C, Leon A, Rahman I, Leval A Eur J Haematol. 2024; 114(1):129-138.

PMID: 39382375 PMC: 11613582. DOI: 10.1111/ejh.14311.

Metallosis-Induced Warm Antibody Auto-Immune Hemolytic Anemia After Bilateral, Large-Diameter Metal-on-Metal Total Hip Arthroplasty With Complete Remission After Revision.

Heimann A, Gautier E, Schwab J, Wahl P, Tannast M, Levrat E Arthroplast Today. 2024; 29:101471.

PMID: 39185399 PMC: 11342758. DOI: 10.1016/j.artd.2024.101471.

References

Mannering N, Hansen D, Frederiksen H . Evans syndrome in children below 13 years of age - A nationwide population-based cohort study. PLoS One. 2020; 15(4):e0231284. PMC: 7145102. DOI: 10.1371/journal.pone.0231284. View

Gehrs B, Friedberg R . Autoimmune hemolytic anemia. Am J Hematol. 2002; 69(4):258-71. DOI: 10.1002/ajh.10062. View

Cooper G, Stroehla B . The epidemiology of autoimmune diseases. Autoimmun Rev. 2003; 2(3):119-25. DOI: 10.1016/s1568-9972(03)00006-5. View

Schmidt M, Schmidt S, Adelborg K, Sundboll J, Laugesen K, Ehrenstein V . The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol. 2019; 11:563-591. PMC: 6634267. DOI: 10.2147/CLEP.S179083. View

Bylsma L, Ording A, Rosenthal A, Ozturk B, Fryzek J, Arias J . Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv. 2019; 3(20):2980-2985. PMC: 6849939. DOI: 10.1182/bloodadvances.2019000476. View

Hill Q, Hill A, Berentsen S . Defining autoimmune hemolytic anemia: a systematic review of the terminology used for diagnosis and treatment. Blood Adv. 2019; 3(12):1897-1906. PMC: 6595261. DOI: 10.1182/bloodadvances.2019000036. View

Ocias L, Larsen T, Vestergaard H, Friis L, Abildgaard N, Frederiksen H . Trends in hematological cancer in the elderly in Denmark, 1980-2012. Acta Oncol. 2016; 55 Suppl 1:98-107. DOI: 10.3109/0284186X.2015.1115124. View

Norgard B, Nielsen J, Fonager K, Kjeldsen J, Jacobsen B, Qvist N . The incidence of ulcerative colitis (1995-2011) and Crohn's disease (1995-2012) - based on nationwide Danish registry data. J Crohns Colitis. 2014; 8(10):1274-80. DOI: 10.1016/j.crohns.2014.03.006. View

Jacobson D, Gange S, Rose N, Graham N . Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997; 84(3):223-43. DOI: 10.1006/clin.1997.4412. View

10.

Hansen D, Moller S, Andersen K, Gaist D, Frederiksen H . Evans syndrome in adults - incidence, prevalence, and survival in a nationwide cohort. Am J Hematol. 2019; 94(10):1081-1090. DOI: 10.1002/ajh.25574. View

11.

Laustrup H, Voss A, Green A, Junker P . Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol. 2009; 38(2):128-32. DOI: 10.1080/03009740802419073. View

12.

Gulbis B, Eleftheriou A, Angastiniotis M, Ball S, Surralles J, Castella M . Epidemiology of rare anaemias in Europe. Adv Exp Med Biol. 2010; 686:375-96. DOI: 10.1007/978-90-481-9485-8_22. View

13.

Lima M . Laboratory studies for paroxysmal nocturnal hemoglobinuria, with emphasis on flow cytometry. Pract Lab Med. 2020; 20:e00158. PMC: 7078534. DOI: 10.1016/j.plabm.2020.e00158. View

14.

Skov T, Deddens J, Petersen M, Endahl L . Prevalence proportion ratios: estimation and hypothesis testing. Int J Epidemiol. 1998; 27(1):91-5. DOI: 10.1093/ije/27.1.91. View

15.

Bass G, Tuscano E, Tuscano J . Diagnosis and classification of autoimmune hemolytic anemia. Autoimmun Rev. 2014; 13(4-5):560-4. DOI: 10.1016/j.autrev.2013.11.010. View

16.

Andersson T, Engholm G, Pukkala E, Stenbeck M, Tryggvadottir L, Storm H . Avoidable cancers in the Nordic countries-The impact of alcohol consumption. Eur J Cancer. 2018; 103:299-307. DOI: 10.1016/j.ejca.2018.03.027. View

17.

Lohi S, Mustalahti K, Kaukinen K, Laurila K, Collin P, Rissanen H . Increasing prevalence of coeliac disease over time. Aliment Pharmacol Ther. 2007; 26(9):1217-25. DOI: 10.1111/j.1365-2036.2007.03502.x. View

18.

Garratty G . Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010; 24(4-5):143-50. DOI: 10.1016/j.blre.2010.06.004. View

19.

Klein N, Ray P, Carpenter D, Hansen J, Lewis E, Fireman B . Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2009; 28(4):1062-8. DOI: 10.1016/j.vaccine.2009.10.115. View

20.

Arndt P . Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology. 2014; 30(2):44-54. View